The ADRENAL study protocol: Adjunctive corticosteroid treatment in critically ill patients with septic shock

Critical Care and Resuscitation

Volumn 15, Issue 2, 2013, Pages 83-88

  Venkatesh, Bala ^a,b   Myburgh, John ^c   Finfer, Simon ^d   Webb, Steve A R ^e   Cohen, Jeremy ^f   Bellomo, Rinaldo ^g   McArthur, Colin ^h   Joyce, Christopher J ⁱ   Rajbhandari, Dorrilyn ^c   Glass, Parisa ^c   Harward, Meg ^c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

^e ROYAL PERTH HOSPITAL   (Australia)

^f ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^g AUSTIN HEALTH   (Australia)

^h AUCKLAND CITY HOSPITAL   (New Zealand)

ⁱ PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; HYDROCORTISONE;

ADULT; ARTICLE; AUSTRALIA; CAUSE OF DEATH; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; EUROPE; FOLLOW UP; HUMAN; INDIA; INTENSIVE CARE UNIT; LENGTH OF STAY; MORTALITY; MULTICENTER STUDY; NEW ZEALAND; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SAUDI ARABIA; SEPTIC SHOCK; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS; AUSTRALIA; CAUSE OF DEATH; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EUROPE; FOLLOW-UP STUDIES; HUMANS; HYDROCORTISONE; INDIA; INTENSIVE CARE UNITS; LENGTH OF STAY; NEW ZEALAND; PROSPECTIVE STUDIES; QUALITY OF LIFE; SAUDI ARABIA; SHOCK, SEPTIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84884569939     PISSN: 14412772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Annane D, Aegerter P, Jars-Guincestre MC, Guidet B. Current epidemiology of septic shock: the CUB-Rea Network. Am J Respir Crit Care Med 2003; 168: 165-172.
2. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358: 877-887.
3. Perner A, Haase N, Guttormsen AB, et al. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 2012; 367: 124-134.
4. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366: 2055-2064. doi: 10.1056/NEJMoa1202290.
5. Warren BL, Eid A, Singer P, et al. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286: 1869-1878.
6. Cronin L, Cook DJ, Carlet J, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995; 23: 1430-1439.
7. Lefering R, Neugebauer EA. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995; 23: 1294-1303.
8. Sprung CL, Caralis PV, Marcial EH, et al. A prospective, controlled study. N Engl J Med 1984; 311: 1137-1143.
9. Bone RC, Fisher CJ Jr, Clemmer TP, et al. A controlled clinical trial of highdose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317: 653-658.
10. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock [see comment]. JAMA 2002; 288: 862-871.
11. Bollaert PE, Charpentier C, Levy B, et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998; 26: 645-650.
12. Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 2009; 301: 2362-2375.
13. Annane D, Sebille V, Troche G, et al. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000; 283: 1038-1045.
14. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003; 348: 727-734.
15. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358: 111-124.
16. Watt I, Ledingham IM. Mortality amongst multiple trauma patients admitted to an intensive therapy unit. Anaesthesia 1984; 39: 973-981.
17. Wagner RL, White PF, Kan PB, et al. Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med 1984; 310: 1415-21.
18. Beale R, Janes JM, Brunkhorst FM, et al. Global utilization of low-dose corticosteroids in severe sepsis and septic shock: a report from the PROGRESS registry. Crit Care 2010; 14: R102.
19. Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008; 34: 17-60.
20. Sprung CL. Randomized controlled trials and practice guidelines: the good, the bad, and the ugly. Intensive Care Med 2012; 38: 1911-1913.
21. Venkatesh B, Mortimer RH, Couchman B, Hall J. Evaluation of random plasma cortisol and the low dose corticotropin test as indicators of adrenal secretory capacity in critically ill patients: a prospective study. Anaesth Intensive Care 2005; 33: 201-209.
22. Briegel J, Sprung CL, Annane D, et al. Multicenter comparison of cortisol as measured by different methods in samples of patients with septic shock. Intensive Care Med 2009; 35: 2151-2156.
23. Myburgh JA, Higgins A, Jovanovska A, et al. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med 2008; 34: 2226-2234.
24. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-829.
25. EuroQoL group. EuroQoL-A new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
26. Finfer S, Bellomo R, Lipman J, et al. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med 2004; 30: 589-596.
27. Finfer S, Heritier S. NICE study management committee and SUGAR study executive committee. The NICE-SUGAR (normoglycaemia in intensive care evaluation and survival using glucose algorithm regulation) study: statistical analysis plan. Crit Care Resusc 2009; 11: 46-57.
28. Finfer S, Cass A, Gallagher M, et al. The RENAL (randomised evaluation of normal vs. augmented level of replacement therapy) study: statistical analysis plan. Crit Care Resusc 2009; 11: 58-66.
29. Myburgh J, Li Q, Heritier S, et al. Statistical analysis plan for the Crystalloid Versus Hydroxyethyl Starch Trial (CHEST). Crit Care Resusc 2012; 14: 44-52. Erratum in Crit Care Resusc 2012; 14: 164.